Back to search

University of Sheffield

Issues, Challenges and Opportunities for Economic Evaluation in Rare Diseases

Abstract

dc:description.abstract

Background and objectives Orphan drugs have surged in recent decades, but economic evaluation in rare diseases remains challenging. The main research aim set out to explore issues, challenges and opportunities for economic evaluation in rare disease. Methods A comprehensive umbrella review was undertaken to identify issues and challenges for economic evaluation of orphan drugs, though opportunities emerged as well. The findings were further evaluated in an early health technology assessment of multiple system atrophy (rare disease), which was disseminated as a user-friendly Shiny app. In addition, cost-effectiveness modelling using Markov and partitioned survival models was conducted to further explore opportunities and corroborate challenges. Results The most obvious finding to emerge from the umbrella review was the scarcity of health-economic parameters. It was, moreover, a challenge for cost-effectiveness modelling in multiple system atrophy, e.g., initially for disability scales and later for clinical progression milestones used to inform health states, where health-economic parameters became increasingly scarce. Not surprisingly, a limited quantity of economic evaluations was identified in the umbrella review. Similarly, the evidence synthesis for multiple system atrophy found no economic evaluations despite a wealth of economic evaluations for disease analogues. Discussion Missing health-economic parameters make model development challenging. However, the very first economic evaluation was developed in multiple system atrophy. Early modelling in an iterative modelling framework should guide data collection efforts, e.g., using comprehensive and flexible models. This is important, because timely preparation and data generation is key to address missing health-economic parameters, which cause much difficulty when constructing economic evaluations. Conclusions To conclude, demonstrating the value of orphan drugs in rare diseases is notoriously difficult, because of pertinent challenges such as dealing with data scarcities for health-economic parameters. Solutions are not plentiful and rarely forthcoming; however, opportunities were identified, but they need further development and refinement by future researchers.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Sheffield
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Sydendal Grand, Tobias
Advisors dc:contributor.advisor
  • Kate, Ren
  • Sarah, Davis
  • Praveen, Thokala
ORCID person:identifier.orcid

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Dc Identifier Grantnumber
2040-00017B

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Sydendal Grand, Tobias. Issues, Challenges and Opportunities for Economic Evaluation in Rare Diseases. doctoral thesis, University of Sheffield, 2026.